Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments, and Chronic Lymphocytic Leukemia Research.
Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.
Epigenomic diagnosis and prognosis of Acute Myeloid Leukemia
Genomic profiling of circulating tumor DNA for childhood cancers.
Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.
Clonal Evolution of Pediatric Acute Myeloid Leukemia and Its Contribution to Disease Relapse
A new genomic framework to categorize pediatric acute myeloid leukemia
A new genomic framework to categorize pediatric acute myeloid leukemia.
Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors.
Optimized cytogenetic risk-group stratification of <i>KMT2A</i>-rearranged pediatric acute myeloid leukemia
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.
Severe Sepsis During Treatment for Childhood Leukemia and Sequelae Among Adult Survivors
Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion.
Neurocognitive and psychosocial outcomes in survivors of childhood leukemia with Down syndrome.
Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia.
Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research.
Supplementary Data 1 from Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia
Data from Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i>-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group.
Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia
Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.
Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.
Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML.
Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions.
Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia.
Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia.
SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia.
Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods.
Proposal of a new genomic framework for categorization of pediatric acute myeloid leukemia associated with prognosis
Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis.